Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 629 across all filing types
Latest filing 2025-04-25 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
德勤华永会计师事务所(特殊普通合伙)关于成都先导药物开发股份有限公司财务报表及审计报告
Regulatory Filings
2025-04-25 Chinese
中国国际金融股份有限公司关于成都先导药物开发股份有限公司2024年度募集资金存放与使用情况的专项核查意见
Regulatory Filings
2025-04-25 Chinese
成都先导药物开发股份有限公司2024年年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2024 Annual Special Report on the Deposit and Actual Use of Raised Funds" by Chengdu Lead Drug Development Co., Ltd. It details the management, storage, and actual use of funds raised through an IPO in 2020, including specific figures on funds used and remaining, compliance with regulatory guidelines from the China Securities Regulatory Commission and Shanghai Stock Exchange, and includes a special audit report from Deloitte. The document is a detailed report on the use of capital raised by the company, focusing on the management and deployment of those funds during the fiscal year 2024. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is over 5,000 characters and contains substantive financial data and regulatory compliance information related to fundraising and capital use, not just an announcement or certification. Therefore, the appropriate classification is CAP.
2025-04-25 Chinese
成都先导药物开发股份有限公司第二届董事会第二十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board of directors meeting of Chengdu Lead Drug Development Co., Ltd. It includes approvals of various reports such as the 2024 Annual Report, 2025 First Quarter Report, financial statements audited by Deloitte, profit distribution proposals, internal control evaluation, and other governance and financial matters. The document also references that the actual reports are published separately on the Shanghai Stock Exchange website. The document is not the reports themselves but a formal board meeting resolution announcement covering multiple agenda items including approval of reports and proposals to be submitted to the shareholders' meeting. This fits the category of Board/Management Information (MANG) as it announces board meeting decisions and management-related approvals rather than the reports themselves or their publication announcements. The document length (7184 characters) and content confirm it is a comprehensive board meeting resolution announcement rather than a short report publication notice or the report itself.
2025-04-25 Chinese
北京君合(成都)律师事务所关于成都先导药物开发股份有限公司2023年限制性股票激励计划剩余限制性股票作废事项之法律意见书
Regulatory Filings
2025-04-25 Chinese
成都先导药物开发股份有限公司2024年年度报告
Annual Report Classification · 100% confidence The document is titled "成都先导药物开发股份有限公司 2024 年年度报告" which translates to "HitGen Inc. 2024 Annual Report." It contains detailed financial data for the full fiscal year 2024, including revenue, net profit, quarterly breakdowns, non-recurring gains and losses, and management discussion and analysis. It also includes auditor information and a standard unqualified audit opinion from Deloitte. The document length is substantial (15,000 characters and more), indicating it is the full report rather than a brief announcement. The presence of comprehensive financial statements, management discussion, risk factors, governance, and other sections typical of an annual report confirms this classification. Therefore, this document is an Annual Report (10-K equivalent).
2025-04-25 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.